Saint Cloud, France (ots/PRNewswire) – Ethypharm is pleased to announce the acquisition of a suppository form of mesalazine by its Chinese subsidiary, Shanghai Ethypharm Pharmaceuticals Ltd, from Chinese company Jiangsu Anbison Pharmaceutical.
Ethypharm is a leader in essential medicines for the central nervous system, hospital care and internal medicine and its strategy is to continue to grow in its key markets, the five major European countries and China, as well as internationally with its strong distribution network. The company’s growth will be achieved both through organic growth and through acquisitions.
Mesalazine is a medication used to treat inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease.
Since 1997, Ethypharm has been pioneering the Chinese market for oral mesalazine with Etiasa®, achieving a market share of around 30%.
China is the third largest market for mesalazine worldwide, with mainly oral and topical forms accounting for 20% of the total market.
Treatment with mesalazine suppositories offers advantages such as more targeted release.
The acquisition will enable Ethypharm to better meet the demand of Chinese patients and healthcare professionals for high-quality treatments by offering a complete portfolio of mesalazine forms and extends the life cycle of one of Ethypharm’s leading products.
Denis DELVAL, President and CEO of the Ethypharm Group, stated:This acquisition represents a significant milestone in Ethypharm’s growth strategy and is in line with the company’s commitment to providing patients with essential medicines. It will accelerate Ethypharm’s growth and strengthen Etiasa®’s leading position in the Chinese market.”
About Ethypharm
Ethypharm is a leading mid-sized international pharmaceutical company with strong European roots, manufacturing and supplying essential medicines, with a focus on the central nervous system (severe pain and addiction), hospital care and internal medicine. Our goal is to improve patients’ lives and have a positive impact on society and the environment.
Ethypharm employs 1,700 people in the various pharmaceutical sectors, including 1,400 in the industrial sector
Our six manufacturing sites in France, the UK, Spain and China have expertise in injectable medicines and complex solid oral forms.
With a global presence in 68 countries, the company sells its products directly in Europe and China and maintains strategic partnerships in the EMEA, NA, LATAM and APAC markets.
Ethypharm works closely with authorities and healthcare professionals to ensure that its medicines are used properly and that patients have access to them.
To learn more about Ethypharm, visit and follow us on LinkedIn.
Logo –
Contact for media:
Avril PONNELLE | Group Communication Manager | presse@ethypharm.com | www.ethypharm.com
View original content:
Inquiries & Contact:
+33 6 3051 2527
#Ethypharm #expands #mesalazine #Etiasa #portfolio #China